Kim MS, Liu DQ, Strauss JR, Capodanno I, Yao Z, Fenyk-Melody JE, Franklin RB, Vincent SH
(2003) Metabolism and disposition of gemfibrozil in Wistar and multidrug resistance-asso-
ciated protein 2-deficient TR-rats. Xenobiotica 33:1027–1042
Kirmayer AH, Klide AM, Purvance JE (1984) Malignant hyperthermia in a dog: case report and
review of the syndrome. J Am Vet Med Assoc 185:978–982
Kitamura Y, Koto H, Matsuura S, Kawabata T, Tsuchiya H, Kusuhara H, Tsujimoto H, Sugiyama Y
(2008) Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofena-
dine, quinidine, and loperamide following oral administration in collies. Drug Metab Dispos
36:807–810
Klein L (1975) A hot horse. Vet Anesth 2:41–42
Klein L, Ailes N, Fackelman GE, Kellon E, Rosenberg H (1989) Postanesthetic equine myopathy
suggestive of malignant hyperthermia. A case report. Vet Surg 18:479–482
KuKanich B, Borum SL (2008a) The disposition and behavioral effects of methadone in Grey-
hounds. Vet Anaesth Analg 35:242–248
KuKanich B, Borum SL (2008b) Effects of ketoconazole on the pharmacokinetics and pharmaco-
dynamics of morphine in healthy Greyhounds. Am J Vet Res 69:664–669
KuKanich B, Coetzee JF, Gehring R, Hubin M (2007) Comparative disposition of pharmacologic
markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular
and total body fluid volume of Greyhound and Beagle dogs. J Vet Pharmacol Ther 30:314–319
Lasseur R, Grandemange A, Longin-Sauvageon C, Berny P, Benoit E (2007) Comparison of the
inhibition effect of different anticoagulants on vitamin K epoxide reductase activity from
warfarin-susceptible and resistant rat. Pestic Biochem Physiol 88:203–208
Leach LM, Ellis M, Sutton DS, McKeith FK, Wilson ER (1996) The growth performance, carcass
characteristics, and meat quality of halothane carrier and negative pigs. J Anim Sci 74:934–943
Leary SL, Anderson LC, Manning PJ, Bache RJ, Zweber BA (1983) Recurrent malignant
hyperthermia in a Greyhound. J Am Vet Med Assoc 182:521–522
Leslie EM, Ghibellini G, Nezasa KI, Brouwer KLR (2007) Biotransformation and transport of the
tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in bile
duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR-) Wistar rats. Carcinogenesis
28:2650–2656
MacLennan DH, Phillips MS (1992) Malignant hyperthermia. Science 256:789–794
Manley SV, Kelly AB, Hodgson D (1983) Malignant hyperthermia-like reactions in three
anesthetized horses. J Am Vet Med Assoc 183:85–89
Marsh S, Van Booven DJ (2009) The increasing complexity of mercaptopurine pharmacoge-
nomics. Clin Pharmacol Ther 85:139–141
Martell KJ, Vatsis KP, Weber WW (1991) Molecular genetic basis of rapid and slow acetylation in
mice. Mol Pharmacol 40:218–227
Matsui M, Watanabe HK (1982) Classification and genetic expression of wistar rats with high and
low hepatic microsomal UDP-glucuronosyltransferase activity towards androsterone. Biochem
J 202:171–174
Mealey KL, Meurs KM (2008) Breed distribution of the ABCB1–1D(multidrug sensitivity) poly-
morphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc 233:921–924
Mealey KL, Bentjen SA, Gay JM, Cantor GH (2001) Ivermectin sensitivity in collies is associated
with a deletion mutation of the mdr1 gene. Pharmacogenetics 11:727–733
Mealey KL, Northrup NC, Bentjen SA (2003) Increased toxicity of P-glycoprotein-substrate
chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin
sensitivity. J Am Vet Med Assoc 223(1453–1455):1434
Mealey KL, Munyard KA, Bentjen SA (2005) Frequency of the mutant MDR1 allele associated
with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet Parasitol
131:193–196
Mealey KL, Greene S, Bagley R, Gay J, Tucker R, Gavin P, Schmidt K, Nelson F (2008)
P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a
spontaneous canine P-glycoprotein knockout model. Drug Metab Dispos 36:1073–1079
Comparative and Veterinary Pharmacogenomics 73